

Nanobiotix reported updated Phase 1 trial data for JNJ-1900 in head and neck cancer, showing strong disease control and survival outcomes.
You can purchase shares of Nanobiotix (NASDAQ:NBTX) through any online brokerage.
Other companies in Nanobiotix’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Nanobiotix has a consensus price target of $44.00.
The stock price for Nanobiotix (NASDAQ: NBTX) is $26.92 last updated October 22, 2026 at 9:17 AM EDT.
There are no upcoming dividends for Nanobiotix.
Nanobiotix does not have any upcoming earnings scheduled.
There is no upcoming split for Nanobiotix.
Nanobiotix is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and...